225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience.

Fadi KhreishNiklas EbertMartin RiesStephan MausFlorian RosarHendrik BohnenbergerTobias StemlerMatthias SaarMark BartholomäSamer Ezziddin

Published in: European journal of nuclear medicine and molecular imaging (2019)

Our results suggest that a single course of tandem therapy with low-activity 225Ac-PSMA-617/full-activity 177Lu-PSMA-617 may safely enhance response to PRLT in men with late-stage/end-stage mCRPC while minimizing xerostomia severity. Formal study of this combination is warranted.

Keyphrases

pet ct
pet imaging
positron emission tomography
squamous cell carcinoma
small cell lung cancer
randomized controlled trial
clinical trial
bone marrow
replacement therapy